Drugs / AZD8329
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01225939 | Nov → Dec 2010 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01207089 | Sep → Dec 2010 | obesity disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00935662 | Jul 2009 → Aug 2010 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01225939 ↗ |
| Action | Inhibit | “inhibition of 11β-HSD1 activity” PMID 26218540 ↗ Oct 2015 |
| Route | Oral | “AZD8329 oral solution” NCT00935662 ↗ |